RT Journal Article
SR Electronic
T1 COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.16.22276392
DO 10.1101/2022.06.16.22276392
A1 Epling, Brian P.
A1 Rocco, Joseph M.
A1 Boswell, Kristin L.
A1 Laidlaw, Elizabeth
A1 Galindo, Frances
A1 Kellogg, Anela
A1 Das, Sanchita
A1 Roder, Allison
A1 Ghedin, Elodie
A1 Kreitman, Allie
A1 Dewar, Robin L.
A1 Kelly, Sophie E. M.
A1 Kalish, Heather
A1 Rehman, Tauseef
A1 Highbarger, Jeroen
A1 Rupert, Adam
A1 Kocher, Gregory
A1 Holbrook, Michael R.
A1 Lisco, Andrea
A1 Manion, Maura
A1 Koup, Richard A.
A1 Sereti, Irini
YR 2022
UL http://medrxiv.org/content/early/2022/06/17/2022.06.16.22276392.abstract
AB Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe disease or impaired antibody and T-cell responses in people with rebound symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this study was provided in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients and healthy controls were evaluated at the National Institutes of Health and provided written informed consent and were enrolled on the "COVID-19 Associated Lymphopenia Pathogenesis Study in Blood" or a separate protocol for healthy volunteers (NCT00001281) both of which were approved by the National Institutes of Health Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript